Rosiglitazone Metabolism in Human Liver Microsomes Using a Substrate Depletion Method

Maryam Bazargan, David J R Foster, Andrew K. Davey, Beverly S. Muhlhausler

    Research output: Contribution to journalArticle

    1 Citation (Scopus)

    Abstract

    Background: Elimination of rosiglitazone in humans is via hepatic metabolism. The existing studies suggest that CYP2C8 is the major enzyme responsible, with a minor contribution from CYP2C9; however, other studies suggest the involvement of additional cytochrome P450 enzymes and metabolic pathways. Thus a full picture of rosiglitazone metabolism is unclear. Objective: This study aimed to improve the current understanding of potential drug–drug interactions and implications for therapy by evaluating the kinetics of rosiglitazone metabolism and examining the impact of specific inhibitors on its metabolism using the substrate depletion method. Methods: In vitro oxidative metabolism of rosiglitazone in human liver microsomes obtained from five donors was determined over a 0.5–500 µM substrate range including the contribution of CYP2C8, CYP2C9, CYP3A4, CYP2E1, and CYP2D6. Results: The maximum reaction velocity was 1.64 ± 0.98 nmol·mg−1·min−1. The CYP2C8 (69 ± 20%), CYP2C9 (42 ± 10%), CYP3A4 (52 ± 23%), and CEP2E1 (41 ± 13%) inhibitors all significantly inhibited rosiglitazone metabolism. Conclusion: The results suggest that other cytochrome P450 enzymes, including CYP2C9, CYP3A4, and CEP2E1, in addition to CYP28, also play an important role in the metabolism of rosiglitazone. This example demonstrates that understanding the complete metabolism of a drug is important when evaluating the potential for drug–drug interactions and will assist to improve the current therapeutic strategies.

    LanguageEnglish
    Pages189-198
    Number of pages10
    JournalDrugs in R and D
    Volume17
    Issue number1
    DOIs
    Publication statusPublished - 1 Mar 2017

    ASJC Scopus subject areas

    • Pharmacology

    Cite this

    Bazargan, Maryam ; Foster, David J R ; Davey, Andrew K. ; Muhlhausler, Beverly S. / Rosiglitazone Metabolism in Human Liver Microsomes Using a Substrate Depletion Method. In: Drugs in R and D. 2017 ; Vol. 17, No. 1. pp. 189-198.
    @article{b240dad52ca54a95b18cca6be74c88fa,
    title = "Rosiglitazone Metabolism in Human Liver Microsomes Using a Substrate Depletion Method",
    abstract = "Background: Elimination of rosiglitazone in humans is via hepatic metabolism. The existing studies suggest that CYP2C8 is the major enzyme responsible, with a minor contribution from CYP2C9; however, other studies suggest the involvement of additional cytochrome P450 enzymes and metabolic pathways. Thus a full picture of rosiglitazone metabolism is unclear. Objective: This study aimed to improve the current understanding of potential drug–drug interactions and implications for therapy by evaluating the kinetics of rosiglitazone metabolism and examining the impact of specific inhibitors on its metabolism using the substrate depletion method. Methods: In vitro oxidative metabolism of rosiglitazone in human liver microsomes obtained from five donors was determined over a 0.5–500 µM substrate range including the contribution of CYP2C8, CYP2C9, CYP3A4, CYP2E1, and CYP2D6. Results: The maximum reaction velocity was 1.64 ± 0.98 nmol·mg−1·min−1. The CYP2C8 (69 ± 20{\%}), CYP2C9 (42 ± 10{\%}), CYP3A4 (52 ± 23{\%}), and CEP2E1 (41 ± 13{\%}) inhibitors all significantly inhibited rosiglitazone metabolism. Conclusion: The results suggest that other cytochrome P450 enzymes, including CYP2C9, CYP3A4, and CEP2E1, in addition to CYP28, also play an important role in the metabolism of rosiglitazone. This example demonstrates that understanding the complete metabolism of a drug is important when evaluating the potential for drug–drug interactions and will assist to improve the current therapeutic strategies.",
    author = "Maryam Bazargan and Foster, {David J R} and Davey, {Andrew K.} and Muhlhausler, {Beverly S.}",
    year = "2017",
    month = "3",
    day = "1",
    doi = "10.1007/s40268-016-0166-4",
    language = "English",
    volume = "17",
    pages = "189--198",
    journal = "Drugs in R and D",
    issn = "1174-5886",
    publisher = "Adis International Ltd",
    number = "1",

    }

    Rosiglitazone Metabolism in Human Liver Microsomes Using a Substrate Depletion Method. / Bazargan, Maryam; Foster, David J R; Davey, Andrew K.; Muhlhausler, Beverly S.

    In: Drugs in R and D, Vol. 17, No. 1, 01.03.2017, p. 189-198.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Rosiglitazone Metabolism in Human Liver Microsomes Using a Substrate Depletion Method

    AU - Bazargan, Maryam

    AU - Foster, David J R

    AU - Davey, Andrew K.

    AU - Muhlhausler, Beverly S.

    PY - 2017/3/1

    Y1 - 2017/3/1

    N2 - Background: Elimination of rosiglitazone in humans is via hepatic metabolism. The existing studies suggest that CYP2C8 is the major enzyme responsible, with a minor contribution from CYP2C9; however, other studies suggest the involvement of additional cytochrome P450 enzymes and metabolic pathways. Thus a full picture of rosiglitazone metabolism is unclear. Objective: This study aimed to improve the current understanding of potential drug–drug interactions and implications for therapy by evaluating the kinetics of rosiglitazone metabolism and examining the impact of specific inhibitors on its metabolism using the substrate depletion method. Methods: In vitro oxidative metabolism of rosiglitazone in human liver microsomes obtained from five donors was determined over a 0.5–500 µM substrate range including the contribution of CYP2C8, CYP2C9, CYP3A4, CYP2E1, and CYP2D6. Results: The maximum reaction velocity was 1.64 ± 0.98 nmol·mg−1·min−1. The CYP2C8 (69 ± 20%), CYP2C9 (42 ± 10%), CYP3A4 (52 ± 23%), and CEP2E1 (41 ± 13%) inhibitors all significantly inhibited rosiglitazone metabolism. Conclusion: The results suggest that other cytochrome P450 enzymes, including CYP2C9, CYP3A4, and CEP2E1, in addition to CYP28, also play an important role in the metabolism of rosiglitazone. This example demonstrates that understanding the complete metabolism of a drug is important when evaluating the potential for drug–drug interactions and will assist to improve the current therapeutic strategies.

    AB - Background: Elimination of rosiglitazone in humans is via hepatic metabolism. The existing studies suggest that CYP2C8 is the major enzyme responsible, with a minor contribution from CYP2C9; however, other studies suggest the involvement of additional cytochrome P450 enzymes and metabolic pathways. Thus a full picture of rosiglitazone metabolism is unclear. Objective: This study aimed to improve the current understanding of potential drug–drug interactions and implications for therapy by evaluating the kinetics of rosiglitazone metabolism and examining the impact of specific inhibitors on its metabolism using the substrate depletion method. Methods: In vitro oxidative metabolism of rosiglitazone in human liver microsomes obtained from five donors was determined over a 0.5–500 µM substrate range including the contribution of CYP2C8, CYP2C9, CYP3A4, CYP2E1, and CYP2D6. Results: The maximum reaction velocity was 1.64 ± 0.98 nmol·mg−1·min−1. The CYP2C8 (69 ± 20%), CYP2C9 (42 ± 10%), CYP3A4 (52 ± 23%), and CEP2E1 (41 ± 13%) inhibitors all significantly inhibited rosiglitazone metabolism. Conclusion: The results suggest that other cytochrome P450 enzymes, including CYP2C9, CYP3A4, and CEP2E1, in addition to CYP28, also play an important role in the metabolism of rosiglitazone. This example demonstrates that understanding the complete metabolism of a drug is important when evaluating the potential for drug–drug interactions and will assist to improve the current therapeutic strategies.

    UR - http://www.scopus.com/inward/record.url?scp=85009200773&partnerID=8YFLogxK

    U2 - 10.1007/s40268-016-0166-4

    DO - 10.1007/s40268-016-0166-4

    M3 - Article

    VL - 17

    SP - 189

    EP - 198

    JO - Drugs in R and D

    T2 - Drugs in R and D

    JF - Drugs in R and D

    SN - 1174-5886

    IS - 1

    ER -